Nuclidium key facts
as of Oct 2026- Developer of novel radiopharmaceutical tracers designed to target cancer diagnostics.
- Nuclidium is valued at approximately $163.2M as of Oct 2026 (last reported valuation).
- It has raised $100.6M; the latest was Later Stage VC ($97.7M) in Jul 2025.
- Notable investors include Innosuisse, Bayern Kapital, Highlight Capital, NRW.Bank, Kurma Partners — 13 tracked in total.
- Status: Privately Held (backing).
Nuclidium's last reported valuation, Jul 2025. Nothing priced has surfaced since.
- ·The complete investor list: 13 names
- ·Watch Nuclidium: the Monday email on marks, rounds and moves
Nuclidium funding rounds
No funding rounds for Nuclidium are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Nuclidium
13+Membership and data by Private Market View
Nuclidium valuation
Nuclidium's last reported valuation was $163 million in Jul 2025. No priced round, secondary trade or fund mark has surfaced since.
Nuclidium investors
13 investors are on record for Nuclidium, including Innosuisse, Bayern Kapital, Highlight Capital and NRW.Bank. By type, the record holds 5 venture capital firms.
About Nuclidium
Developer of novel radiopharmaceutical tracers designed to target cancer diagnostics. The company's platform provides new diagnostic and therapeutic tracers in which specific target molecules will first be detected on the patient's tumor and can be treated with similar chemical properties and the same biological molecular targets, enabling the patients to access affordable and effective personalized treatment.
- Sector
- Healthcare
- HQ
- Basel, Switzerland
- Founded
- 2017
- Employees
- 8
- Website
- nuclidium.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.